Contact Us
Drug Search Results
More Filters [+]

OMS-405

Alternative Names: OMS-405, OMS405, OMS 405
Latest Update: 2023-06-27
Latest Update Note: News Article

Product Description

OMS-405 is a small-molecule peroxisome proliferator-activated receptor gamma (PPARgamma ) agonist. (Sourced from: https://www.omeros.com/pipeline/#OMS405)

Mechanisms of Action: PPARg Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Omeros
Company Location: SEATTLE WA 98119
Company CEO: Gregory A. Demopulos
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for OMS-405

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Opioid-Related Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

06/27/2023

News Article

 Outlook on the Smoking Cessation and Nicotine Addiction Global Market to 2032 - Market Insight, Epidemiology And Market Forecast

09/28/2021

News Article

 Cocaine Use Disorder Pipeline Evolves as Novel Therapeutic Assets Enter the Market

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions